E
TRDA icon

Ergoteles’s Entrada Therapeutics TRDA Stock Holding History

Ergoteles’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-14,019
Closed -$190K – 1755
2022
Q4 		$190K Buy
+14,019
New +$246K 0.01% 1090
2022
Q3 		– Sell
-18,807
Closed -$229K – 1990
2022
Q2 		$229K Buy
+18,807
New +$143K 0.01% 1251

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Ergoteles's TRDA Position: Q1 2023 in Review

Ergoteles sold out of Entrada Therapeutics (TRDA) in Q1 2023, closing a stake of 14,019 shares — an estimated $190K sold.

Ergoteles first reported a position in TRDA in Q2 2022 and held it in 2 quarters. The position peaked at $229K in Q2 2022. 52 funds tracked by Wall St. Rank hold TRDA as of Q1 2023.

  • Ergoteles reported no remaining Entrada Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Ergoteles sold 14,019 Entrada Therapeutics shares in Q1 2023, an estimated $190K.
  • Ergoteles first reported a position in Entrada Therapeutics in Q2 2022 and held it in 2 quarters.
  • Ergoteles's Entrada Therapeutics position peaked at $229K in Q2 2022.
  • 52 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.